Faecal Microbiota Transplantation Reduces Lesion Severity and Medication Use in Canine Atopic Dermatitis: A Randomised, Placebo-Controlled, Double-Blinded Clinical Trial
Adjunctive oral and rectal FMT reduced skin lesion severity scores and symptomatic medication use in dogs with atopic dermatitis over 90 days.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
CADESI-04 scores were significantly lower in the FMT group at months 2 and 3 compared to placebo. Sustained responders (≥50% CADESI-04 improvement at M2 and M3) were more frequent with FMT (35% vs. 5%). Medication scores were also lower in the FMT group at the same time points.
How it was done
Prospective, randomised, double-blinded, placebo-controlled clinical trial enrolling 46 dogs (40 completed); animals received daily oral lyophilised FMT capsules for 90 days plus three monthly rectal administrations, or matched placebo.
Risk of bias
The sample is small (n=40 completers) and drawn from a referral hospital, limiting generalisability. The abstract does not report complete PVAS or OGATE outcomes, nor detailed safety data.
What this study does NOT prove
This study does not prove that FMT is effective as monotherapy for canine atopic dermatitis or that benefits persist beyond 90 days.
In clinical practice
Results support FMT as a potentially useful adjunctive approach, but the small sample and incomplete data in the abstract warrant caution before broad clinical adoption.
Limitations
The sample is small (n=40 completers) and drawn from a referral hospital, limiting generalisability. The abstract does not report complete PVAS or OGATE outcomes, nor detailed safety data.
Technical appendix
Version history
- 1.0 · 2026-09-05 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.